Finally, determining the actual topography of what domains of vimentin are expressed on the surface of prostate and other metastatic cancer cells could provide insights for the creation of novel therapeutic antibody agents, such as spectral-targeted antibody derivative constructs [46]. This evidence concerns the gene VIM and metastatic malignant neoplasm.